Tuesday, December 26. 2006
I recommend AmeriSciences Omega Max for Depression. Here is an abstract below supporting its use for Depression. Sultan H. Rahaman, M.D.President Wellness for Life Center, Inc.www.wellnessforlifecenter.org info@wellnessforlifecenter.org Biol Psychiatry. 2006 Dec 21; [Epub ahead of print] Selective Deficits in the Omega-3 Fatty Acid Docosahexaenoic Acid in the Postmortem Orbitofrontal Cortex of Patients with Major Depressive Disorder.Department of Psychiatry, University of Cincinnati College of Medicine. BACKGROUND: Epidemiological surveys and peripheral tissue (red blood cells/plasma) fatty acid composition studies suggest that omega-3 fatty acid deficiency is associated with major depressive disorder (MDD) and suicide. It was hypothesized that patients with MDD would exhibit lower frontal cortical concentrations of docosahexaenoic acid (DHA), the principal omega-3 fatty acid in brain, relative to normal controls. METHODS: We determined the total fatty acid composition of postmortem orbitofrontal cortex (Brodmann's Area 10) from patients with DSM-IV-defined MDD (n = 15) and age-matched normal controls (n = 27) by gas chromatography. RESULTS: After correction for multiple comparisons, the omega-3 fatty acid DHA was the only fatty acid that was significantly different (-22%) in the postmortem orbitofrontal cortex of MDD patients relative to normal controls. Deficits in DHA concentrations were greater in female MDD patients (-32%) than in male MDD patients (-16%), and could not be wholly attributed to lifestyle factors or postmortem tissue variables. CONCLUSIONS: These results demonstrate a selective deficit in the omega-3 fatty acid DHA in the orbitofrontal cortex of patients with MDD. This finding adds to a growing body of evidence implicating omega-3 fatty acid deficiency as well as the orbitofrontal cortex in the pathophysiology and potentially pathogenesis of MDD. PMID: 17188654 [PubMed - as supplied by publisher] Purchase AmeriSciences Omega Max at: www.amerisciencesproducts.com
Tuesday, November 28. 2006
SCIENTIFICAMERICAN.COMFebruary 20, 2006 | | Unlocking the Secrets of Longevity Genes | | A handful of genes that control the body's defenses during hard times can also dramatically improve health and prolong life in diverse organisms. Understanding how they work may reveal the keys to extending human life span while banishing diseases of old age | | By David A. Sinclair and Lenny Guarente
| | You can assume quite a bit about the state of a used car just from its mileage and model year. The wear and tear of heavy driving and the passage of time will have taken an inevitable toll. The same appears to be true of aging in people, but the analogy is flawed because of a crucial difference between inanimate machines and living creatures: deterioration is not inexorable in biological systems, which can respond to their environments and use their own energy to defend and repair themselves. At one time, scientists believed aging to be not just deterioration but an active continuation of an organism's genetically programmed development. Once an individual achieved maturity, "aging genes" began to direct its progress toward the grave. This idea has been discredited, and conventional wisdom now holds that aging really is just wearing out over time because the body's normal maintenance and repair mechanisms simply wane. Evolutionary natural selection, the logic goes, has no reason to keep them working once an organism has passed its reproductive age. Yet we and other researchers have found that a family of genes involved in an organism's ability to withstand a stressful environment, such as excessive heat or scarcity of food or water, have the power to keep its natural defense and repair activities going strong regardless of age. By optimizing the body's functioning for survival, these genes maximize the individual's chances of getting through the crisis. And if they remain activated long enough, they can also dramatically enhance the organism's health and extend its life span. In essence, they represent the opposite of aging genes--longevity genes. We began investigating this idea nearly 15 years ago by imagining that evolution would have favored a universal regulatory system to coordinate this well-known response to environmental stress. If we could identify the gene or genes that serve as its master controllers and thereby act as master regulators of an organism's life span, these natural defense mechanisms might be turned into weapons against the diseases and decline that are now apparently synonymous with human aging. Many recently discovered genes, known by such cryptic names as daf-2, pit-1, amp-1, clk-1 and p66Shc, have been found to affect stress resistance and life span in laboratory organisms, suggesting that they could be part of a fundamental mechanism for surviving adversity. But our own two laboratories have focused on a gene called SIR2, variants of which are present in all organisms studied so far, from yeast to humans. Extra copies of the gene increase longevity in creatures as diverse as yeast, roundworms and fruit flies, and we are working to determine whether it does the same for larger animals, such as mice. As one of the first longevity genes to have been identified, SIR2 is the best characterized, so we will focus here on its workings. They illustrate how a genetically regulated survival mechanism can extend life and improve health, and growing evidence suggests that SIR2 may be the key regulator of that mechanism. Silence Is Golden We first discovered that SIR2 is a longevity gene by asking what causes individual baker's yeast cells to grow old and whether a single gene might control aging in this simple organism. The notion that an understanding of yeast life span would tell us anything about human aging was deemed preposterous by many. Aging in yeast is measured by counting how many times mother cells divide to produce daughters before dying. A typical yeast cell's life span is about 20 divisions. One of us (Guarente) began by screening yeast colonies for unusually long-lived cells in the hope of finding genes responsible for their longevity. This screen yielded a single mutation in a gene called SIR4, which encodes part of a complex of proteins containing the Sir2 enzyme. The mutation in SIR4 caused the Sir2 protein to gather at the most highly repetitive region of the yeast genome, a stretch containing the genes that encode the protein factories of the cell, known as ribosomal DNA (rDNA). More than 100 of these rDNA repeats exist in the average yeast cell's genome, and they are difficult to maintain in a stable state. Repetitive sequences are prone to "recombining" with one another, a process that in humans can lead to numerous illnesses, such as cancer and Huntington's disease. Our yeast findings suggested that aging in mother cells was caused by some form of rDNA instability that was mitigated by the Sir proteins.
In fact, we found a surprising kind of rDNA instability. After dividing several times, yeast mother cells spin off extra copies of the rDNA as circular rings that pop out of the genome. These extrachromosomal rDNA circles (ERCs) are copied along with the mother cell's chromosomes prior to cell division but remain in the mother cell's nucleus afterward. Thus, a mother cell accumulates an ever increasing number of circles that eventually spell her doom, possibly because copying the ERCs consumes so many resources that she can no longer manage to replicate her own genome. When an extra copy of the SIR2 gene was added to the yeast cell, however, formation of the rDNA circles was repressed and the cell's life span was extended by 30 percent. That finding explained how sir2 could act as a longevity gene in yeast, but amazingly, we soon discovered that extra copies of the sir2 gene also extended the life span of roundworms by as much as 50 percent. We were surprised not only by this commonality in organisms separated by a vast evolutionary distance but by the fact that the adult worm body contains only nondividing cells--thus, the replicative aging mechanism in yeast could not apply to worms. We wanted to know exactly what the SIR2 gene does. As we soon discovered, the gene encodes an enzyme with a completely novel activity. Cellular DNA is wrapped around a complex of packaging proteins called histones. These bear chemical tags, such as acetyl groups, that determine how snugly the histones package DNA. Removing acetyl groups from histones tightens the packaging further and renders the DNA inaccessible to the enzymes responsible for popping the rDNA circles out of the chromosome. This deacetylated form of DNA is said to be silent because any genes in these regions of the genome are rendered inaccessible to being activated. Sir proteins were already known to be involved in gene silencing--indeed, SIR stands for silent information regulator. Sir2 is one of several enzymes that remove acetyl tags from the histones, but we discovered that it is unique in that its enzymatic activity absolutely requires a ubiquitous small molecule called NAD, which has long been known as a conduit of many metabolic reactions in cells. This association between Sir2 and NAD was exciting because it linked Sir2 activity to metabolism and thus potentially to the relation between diet and aging observed in calorie restriction. The Calorie Connection Restricting an animal's calorie intake is the most famous intervention known to extend life span. Discovered more than 70 years ago, it is still the only one absolutely proven to work. The restricted regime typically involves reducing an individual's food consumption by 30 to 40 percent compared with what is considered normal for its species. Animals ranging from rats and mice to dogs and possibly primates that remain on this diet not only live longer but are far healthier during their prolonged lives. Most diseases, including cancer, diabetes and even neurodegenerative illnesses, are forestalled. The organism seems to be supercharged for survival. The only apparent trade-off in some creatures is a loss of fertility. Understanding the mechanisms by which calorie restriction works and developing medicines that reproduce its health benefits have been tantalizing goals for decades [see "The Serious Search for an Antiaging Pill," by Mark A. Lane, Donald K. Ingram and George S. Roth; Scientific American: The Science of Staying Young, 2004]. The phenomenon was long attributed to a simple slowing down of metabolism--cells' production of energy from fuel molecules--and therefore reduction of its toxic by-products in response to less food. But this view now appears to be incorrect. Calorie restriction does not slow metabolism in mammals, and in yeast and worms, metabolism is both sped up and altered by the diet. We believe, therefore, that calorie restriction is a biological stressor like natural food scarcity that induces a defensive response to boost the organism's chances of survival. In mammals, its effects include changes in cellular defenses, repair, energy production and activation of programmed cell death known as apoptosis. We were eager to know what part Sir2 might play in such changes, so we looked first at its role during calorie restriction in simple organisms. In yeast, we have found that restricting food availability affects two pathways that increase Sir2 enzymatic activity in the cells. On one hand, calorie restriction turns on a gene called PNC1, which produces an enzyme that rids cells of nicotinamide, a small molecule similar to vitamin B3 that normally represses Sir2. Consistent with the idea that calorie restriction is a stressor that activates a survival response, PNC1 is also stimulated by other mild stressors known to extend yeast life span, such as increased temperature or excessive amounts of salt. A second pathway induced in yeast by restricted calories is respiration, a mode of energy production that creates NAD as a by-product while lowering levels of its counterpart, NADH. It turns out that not only does NAD activate Sir2, but NADH is an inhibitor of the enzyme, so altering the cell's NAD/NADH ratio profoundly influences Sir2 activity. Having seen how life-extending biological stress increases Sir2 activity, the question became, Is Sir2 necessary to produce the longevity? The answer appears to be a resounding "yes." One way to test whether Sir2 is essential to this process is to remove its gene and determine whether the effect remains. In organisms as complex as fruit flies, calorie restriction does require SIR2 to extend life span. And because the body of an adult fruit fly contains numerous tissues that are analogous to mammalian organs, we suspect that calorie restriction in mammals is also likely to require SIR2. Yet if humans are ever to reap the health benefits of calorie restriction, radical dieting is not a reasonable option. Drugs that can modulate the activity of Sir2 and its siblings (collectively referred to as Sirtuins) in a similar manner will be needed. Just such a Sirtuin-activating compound, or STAC, called resveratrol has proven particularly interesting. Resveratrol is a small molecule present in red wine and manufactured by a variety of plants when they are stressed. At least 18 other compounds produced by plants in response to stress have also been found to modulate Sirtuins, suggest?-ing that the plants may use such mole?-cules to control their own Sir2 enzymes. Feeding resveratrol to yeast, worms or flies or placing them on a calorie-restricted diet extends their life spans about 30 percent, but only if they possess the SIR2 gene. Moreover, a fly that overproduces Sir2 has an increased life span that cannot be further extended by resveratrol or calorie restriction. The simplest interpretation is that calorie restriction and resveratrol each prolong the lives of fruit flies by activating Sir2. Resveratrol-fed flies not only live longer, despite eating as much as they want, but they do not suffer from the reduced fertility often caused by calorie restriction. This is welcome news for those of us hoping to treat human diseases with molecules that target Sir2 enzymes. But first we want a better understanding of the role of Sir2 in mammals. Leader of the Band The mammalian version of the yeast SIR2 gene is known as SIRT1 ("SIR2 homolog 1"). It encodes a protein, Sirt1, that has the same enzymatic activity as Sir2 but that also deacetylates a wider variety of proteins both inside the cell nucleus and out in the cellular cytoplasm. Several of these proteins targeted by Sirt1 have been identified and are known to control critical processes, including apoptosis, cell defenses and metabolism. The potential longevity-enhancing role of the SIR2 gene family seems, therefore, to be preserved in mammals. But not surprisingly in larger and more complex organisms, the pathways by which Sirtuins achieve their effect have grown considerably more complicated as well. Increased Sirt1 in mice and rats, for example, allows some of the animals' cells to survive in the face of stress that would normally trigger their programmed suicide. Sirt1 does this by regulating the activity of several other key cellular proteins, such as p53, FoxO and Ku70, that are involved either in setting a threshold for apoptosis or in prompting cell repair. Sirt1 thus enhances cellular repair mechanisms while buying time for them to work. Over the course of a lifetime, cell loss from apoptosis may be an important factor in aging, particularly in nonrenewable tissues such as the heart and brain, and slowing cell death may be one way Sirtuins promote health and longevity. A striking example of Sirt1's ability to foster survival in mammalian cells can be seen in the Wallerian mutant strain of mouse. In these mice, a single gene is duplicated, and the mutation renders their neurons highly resistant to stress, which protects them against stroke, chemotherapy-induced toxicity and neurodegenerative diseases. In 2004 Jeffrey D. Milbrandt of Washington University in St. Louis and his colleagues showed that the Wallerian gene mutation in these mice increases the activity of an enzyme that makes NAD, and the additional NAD appears to protect the neurons by activating Sirt1. Moreover, Milbrandt's group found that STACs such as resveratrol conferred a protective effect on the neurons of normal mice similar to the Wallerian mutation. In a more recent study by Christian N鲩 of the French National Institute of Health and Medical Research, resveratrol and another STAC, fisetin, were shown to prevent nerve cells from dying in two different animal models (worm and mouse) of human Huntington's disease. In both cases, the protection by STACs required Sirtuin gene activity. The protective effect of Sirtuins in individual cells is becoming increasingly clear. But if these genes are the mediators of calorie restriction's benefits, an unsolved puzzle remains how diet can regulate their activities and thus the rate of aging in an entire animal. Recent research by Pere Puigserver of the Johns Hopkins University School of Medicine and his colleagues has shown that NAD levels rise in liver cells under fasting conditions, prompting increased Sirt1 activity. Among the proteins Sirt1 acts on is an important regulator of gene transcription called PGC-1, which then causes changes in the cell's glucose metabolism. Thus, Sirt1 was found to act both as a sensor of nutrient availability and a regulator of the liver's response. Similar data have given rise to the idea that Sirt1 is a central metabolic regulator in liver, muscle and fat cells because it senses dietary variations via changes in the NAD/NADH ratio within cells and then exerts far-reaching effects on the pattern of gene transcription in those tissues. This model would explain how Sirt1 may integrate many of the genes and pathways that affect longevity described on page 54. More than one mechanism may mediate Sirt1's bodywide activities, however. Another appealing hypothesis is that mammals register their food availability by the amount of energy they have stored in the form of body fat. Fat cells secrete hormones that convey signals to the other tissues in the body, but their message depends on the levels of fat stored. By reducing fat stores, calorie restriction may establish a pattern of hormone signals that communicates "scarcity," which activates cell defenses. Consistent with this idea is the fact that mice genetically engineered to be extra lean regardless of their food intake tend to live longer. This possibility led us to wonder whether Sirt1, in turn, also regulates fat storage in response to diet. Indeed, Sirt1 activity is increased in fat cells after food limitation, causing fat stores to move from the cells into the bloodstream for conversion to energy in other tissues. We surmise that Sirt1 senses the diet, then dictates the level of fat storage and thus the pattern of hormones produced by fat cells. This effect on fat and the signals it sends would, in turn, set the pace of aging in the entire organism and make Sirt1 a key regulator of the longevity conferred by calorie restriction in mammals. It would also closely link aging and metabolic diseases, including type 2 diabetes, associated with excess fat. Intervening pharmacologically in the Sirt1 pathway in fat cells might therefore forestall not only aging but also specific ailments. Another critical process modified by Sirt1 is inflammation, which is involved in a number of disorders, including cancer, arthritis, asthma, heart disease and neurodegeneration. Recent work by Martin W. Mayo and his colleagues at the University of Virginia has shown that Sirt1 inhibits NF-B, a protein complex that promotes the inflammatory response. The Sirt1-activating compound resveratrol has the same effect. This finding is particularly encouraging, both because the search for molecules that inhibit NF-B is a highly active area of drug development and because another well-known effect of calorie restriction is its ability to suppress excessive inflammation. If SIR2 is thus the master controller of a regulatory system for aging that is activated by stress, it may function by acting as the conductor of an orchestra of players that includes hormonal networks, intracellular regulatory proteins and other genes associated with longevity. One of the more notable discoveries in recent years was that Sirt1 regulates production of insulin and insulinlike growth factor 1 (IGF-1) and that those two powerful signaling molecules, in turn, seem to regulate Sirt1 production as part of a complex feedback loop. The relation between Sirt1, IGF-1 and insulin is intriguing because it explains how Sirt1 activity in one tissue might be communicated to other cells in the body. Moreover, circulating levels of insulin and IGF-1 are known to dictate life span in various organisms--worms, flies, mice, possibly ourselves. From Defense to Advance Because people have sought to slow aging for tens of thousands of years without success, some may find it hard to accept that human aging might be controlled by tweaking a handful of genes. Yet we know it is possible to forestall aging in mammals with a simple dietary change: calorie restriction works. And we have shown that Sirtuin genes control many of the same molecular pathways as calorie restriction. Without actually knowing the precise, and potentially myriad, causes of aging, we have already demonstrated in a variety of life-forms that it can be delayed by manipulating a few regulators and letting them take care of the organisms' health. We also know that the SIR2 family of genes evolved far back in time because today they are found in organisms ranging from baker's yeast, Leishmania parasites and roundworms to flies and humans. In all these organisms but the last, which has not yet been tested, Sirtuins dictate length of life. This fact alone convinces us that human Sirtuin genes probably hold the key to our health and longevity as well. Both our labs are running carefully controlled mouse experiments that should soon tell us whether the SIRT1 gene controls health and life span in a mammal. We will not know definitively how Sirtuin genes affect human longevity for decades. Those who are hoping to pop a pill and live to 130 may have therefore been born a bit too early. Nevertheless, those of us already alive could live to see medications that modulate the activity of Sirtuin enzymes employed to treat specific conditions such as Alzheimer's, cancer, diabetes and heart disease. In fact, several such drugs have begun clinical trials for treatment of diabetes, herpes and neurodegenerative diseases. And in the longer term, we expect that unlocking the secrets of longevity genes will allow society to go beyond treating illnesses associated with aging and prevent them from arising in the first place. It may seem hard to imagine what life will be like when people are able to feel youthful and live relatively free of today's diseases well into their 90s. Some may wonder whether tinkering with human life span is even a good idea. But at the beginning of the 20th century, life expectancy at birth was around 45 years. It has risen to about 75 thanks to the advent of antibiotics and public health measures that allow people to survive or avoid infectious diseases. Society adapted to that dramatic change in average longevity, and few people would want to return to life without those advances. No doubt, future generations accustomed to living past 100 will also look back at our current approaches to improving health as primitive relics of a bygone era. | | © 1996-2006 Scientific American, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited. | |
Thursday, November 16. 2006
November 16, 2006 Journal Reports That Drug Doubles Endurance Given that some athletes will take almost anything to gain a one percent edge in performance, what might they do for a 100 percent improvement? That temptation is made somewhat more real by a report today in a leading journal about a drug that doubles the physical endurance of mice running on treadmills. And it could only be more tempting, because the drug in question has also been reported to extend the lifespan of mice. An ordinary lab mouse will run about one kilometer — five-eights of a mile — on a treadmill before collapsing from exhaustion. But mice given resveratrol, a minor component of red wine and other foods, run twice as far. They also have a reduced heart rate and energy-charged muscles, just as trained athletes do, according to an article published online in Cell by Johan Auwerx and his colleagues at the Institute of Genetics and Molecular and Cellular Biology in Illkirch, France. “Resveratrol makes you look like a trained athlete without the training,” Dr. Auwerx (pronounced OH-wer-ix”) said in an interview. He and his colleagues said the same mechanism seems likely to operate in humans, based on their analysis, in a group of Finnish subjects, of the gene that is influenced by the drug. Their rationale for testing resveratrol was evidence obtained three years ago that it could activate a genetic mechanism known to protect mice against the degenerative diseases of aging and to prolong their lifespan by 30 percent. Dr. Auwerx, whose interest is in the genetic control of metabolism, decided to see if resveratrol would offset the effects of a high-fat diet, specifically the metabolic disturbances, known as metabolic syndrome, that are the precursors of diabetes and obesity. In his report, he and his colleagues say that very large doses of resveratrol protected mice from gaining weight and from developing metabolic syndrome. Dr. Auwerx attributes this change in large part to the significantly increased number of mitochondria he detected in the muscle cells of treated mice. Mitochondria are the organelles within the body’s cells that generate energy. With increased mitochondria, the treated mice were able to burn off more fat and thus avoid weight gain and decreased sensitivity to insulin, Dr. Auwerx said. He found that their muscle fibers had been remodeled by the drug into the type more prevalent in trained human athletes. Dr. Ronald M. Evans, a leading expert on the hormonal control of metabolism at the Salk Institute, said that the report by Dr. Auwerx’s team had “shown very convincingly that resveratrol improves mitochondrial function” and fends off metabolic disease. Dr. Evans described the study as “very important, because it is rare that we identify orally active molecules, especially natural molecules, that have such a broad-based, positive effect on a problem as widespread in society as metabolic disease.” Dr. Ronald Kahn, director of the Joslin Diabetes Center in Boston, said the research would focus attention on the sirtuins, a recently discovered group of enzymes that resveratrol is believed to affect. Noting that he is a scientific advisor to Sirtris, a company developing drugs that activate the sirtuins, Dr. Kahn said, “Certainly, drugs that act on this class of proteins have the potential to have major effects on human disease.” Dr. Auwerx’s study complements one published earlier this month by Dr. David Sinclair of the Harvard Medical School, who found that much more moderate doses of resveratrol protected mice from the metabolic effects of a high-calorie diet. Though his mice did not lose weight, they lived far longer than undosed mice that were fed the same high-calorie diet. The two studies were started and performed independently, Dr. Auwerx said, though he obtained supplies of resveratrol from Sirtris, which was co-founded by Dr. Sinclair, and he has become a scientific advisor to the company. A drug that prolongs life, averts degenerative disease and, on top of all that, makes you into a champion athlete — at least if you are a mouse — sounds almost too good to be true. Dr. Christoph Westphal, Sirtris’s chief executive, replied to this objection with a question: “Is it too good to be true that when you are young you get no disease?” He believes that activation of the sirtuins is what keeps the body healthy in youth, but that these enzymes become less powerful with age, exposing the body to degenerative disease. That is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use. The developing buzz over sirtuin activators has captivated some scientists who do research on the aging process, several of whom are already taking resveratrol themselves. Dr. Sinclair has said that he has been swallowing resveratrol capsules for three years, and that his parents and half his lab staff do the same. So does Dr. Tomas Prolla at the University of Wisconsin. “The fact that investigators in the field are taking it is a good sign there is something there,” he said. But many others believe taking the drug now is premature, including Dr. Leonard Guarente of M.I.T. whose 15-year study of the sirtuins laid the basis for the field of study. It was after working in Dr. Guarente’s lab as a postdoctoral student that Dr. Sinclair found in 2003 that resveratrol was a sirtuin activator. Though resveratrol has long been known to be a component red wine and other foods, it is present there in only minuscule amounts, compared with the very large doses used in experiments. Dr. Sinclair dosed his mice daily with 22 milligrams of resveratrol for each kilogram of weight, and Dr. Auwerx used up to 400 milligrams. No one could drink enough red wine to obtain such doses. Resveratrol is now available in capsules that contain extracts of red wine and giant knotweed, a plant found in China. One manufacturer of such capsules is Longevinex, whose president, Bill Sardi, said today that demand for the product had increased by a factor of 2400 since Nov. 1. But even Longevinex’s capsules, which at present contain 40 milligrams of resveratrol each, would have to be gulped in almost impossible quantities for a human to obtain doses equivalent to those used in mice. “It’s like eating a whole bottle of Tums every day,” Dr. Evans said. Whether much lower doses would benefit athletic performance is not clear, Dr. Evans said. And higher doses may not be as safe as the lower doses found now in foods and “nutraceuticals” like the extract capsules. Besides these uncertainties over what a safe and effective dose of resveratrol might be, the science underlying the field is still in full flux. Many central details are still unclear. The principal theory developed by Dr. Guarente and others is that the sirtuins somehow sense the level of energy expenditure in living cells and switch the body’s resources from reproduction to tissue maintenance when food is low. This is an ancient strategy, Dr. Guarente believes, that allows an organism to live through famines and postpone breeding until good times return. The switch to tissue maintenance involves specific action to stave off the major degenerative diseases of aging, such as cancer, diabetes, heart disease and neurodegeneration. Though resveratrol is in the spotlight, the central focus of researchers is on how the sirtuins are activated and what they do. One serious uncertainty is whether, in the mouse experiments, resverattrol in fact acted through the sirtuins or by some other unknown mechanism. In the latter case, Dr. Sinclair’s and Dr. Auwerx’s mouse experiments would offer less support to the sirtuin theory. Dr. Auwerx cites evidence that resveratrol does activate sirtuin, but Dr. Evans said the case was not yet fully convincing. Dr. Bruce Spiegelman, a Harvard Medical School expert on fat metabolism, said Dr. Auwerx’s paper was “pretty good.” Dr. Auwerx believes resveratrol activates sirtuin, which in turn activates a factor known as PGC1-alpha in a manner first described by Dr. Spiegelman and his colleagues last year. Subsequent actions by PGC1-alpha then stimulate cells to produce more mitochondria. Increased energy production by mitochondria generates potentially dangerous reactive chemicals that are known to damage cells. So it has long been puzzling that exercise, in which energy is expended, is good for health, not bad. Dr. Auwerx noted that Dr. Spiegelman showed in a report in the journal Cell last month that PGC1-alpha not only increases mitochondria, but at the same time generates chemicals that detoxify the energy by-products.
Friday, November 3. 2006
DHA: The Mind Mender - omega-3 fatty acid may aid memory
Is there something fishy going on in your brain? If not, perhaps there should be. Research now shows that eating fish and other foods rich in DHA may boost your brainpower. At a time when we've become so fat-phobic, it's tough to remember that some fats are beneficial. Docosahexaenoic acid (DHA), an omega-3 essential fatty acid, is one of those good fats that health experts say we could eat more of. DHA helps maintain the flexibility of cell membranes, which facilitate communication between brain and nerve cells. High levels of DHA in the brain are associated with optimal brain function--from mental sharpness to memory to mood regulation--while low levels have been linked to Alzheimer's disease, attention deficit disorders and depression. A recent study published in The Lancet showed that in cultures where people consume more fish, there were fewer cases of depression. "The lining of every brain cell is made of fat and fatty acids, and a good chunk of the fatty acids are DHA," explains Ray Sahelian, M.D., author of Mind Boosters (St. Martins, 2000). "It's important that we consume DHA in our diet. Otherwise, the body will substitute other fatty acids, like saturated or monounsaturated fatty acids. Consequently, receptors on cell membranes don't work as efficiently, and the nerve cells don't communicate as well." A recent Japanese study, published in the journal Mechanisms of Aging and Development, makes the point. Scientists fed mice a diet of 5% sardine oil. After 12 months, the mice were able to navigate mazes much faster than were mice eating a diet containing 5% palm oil. And when their brains were later analyzed, those mice consuming sardine oil had much higher levels of DHA than the others. DHA also appears to be heart protective, lowering levels of triglycerides, which have been linked to heart disease. And it's essential for good vision--recent research appearing in the Archives of Ophthalmology found that people who ate more fish had fewer incidences of age-related macular degeneration, which is the leading cause of blindness in older people. Good DHA supplementation starts at birth, as it is abundant in breast milk. You'll also find DHA in salmon, halibut, mackerel, sardines and striped bass as well as flaxseed oil and fish oil supplements. COPYRIGHT 2001 Sussex Publishers, Inc. COPYRIGHT 2001 Gale Group Benefits & Features- Maintains healthy triglyceride levels that are already in the normal range and helps promote healthy neurological and cardiovascular systems
- Promotes healthy eyesight
- Helps fetal brain and nervous development during pregnancy
- Supports the immune system
Supplemental Facts| Serving Size: 2 softgels | | Servings Per Container: 30 | Amount per Serving | % Daily Value | | Vitamin E (as d-alpha tocopherol) | 4 IU | 13% | | Molecularly Distilled Fish Oil (derived from sardine, anchovy, mackerel) | 2000 mg | * | | Provides EPA (elcosapentaenoic acid) | 720 mg | * | | Provides DHA (docosahexaenoic acid) | 480 mg | * | | Total EPA & DHA Omega-3 Fatty Acids | 1200 mg | * | | * Daily value not established | | OTHER INGREDIENTS: Gelatin, purified water, glycerin, methacrylic acid copolymers, triacetin, triethyl citrate, hydroxypropyl methylcellulose, vanilli. |
ContraindicationsKeep out of the reach of children. Consult your physician before taking this product if you take blood thinning medications, or if you anticipate surgery. Directions For Use:Take two (2) to three (3) softgels daily, preferably with meals, or as recommended by a physician.
Wednesday, October 25. 2006
Here is a very useful article from DIVINE.CA to help reduce the risk of Beast Cancer. By Ines Mey
Protect Your Breasts
One in nine Canadian women will develop breast cancer in their lifetime. Help reduce your risks by following these nine simple guidelines. Exercise Fat cells produce estrogen; high levels of this hormone are believed to cause breast cancer. Working out can shrink fat cells and reduce the amount of estrogen that is produced by the body. Even if you've been inactive most of your life, you can greatly reduce your risk of developing breast cancer by becoming active now! Health Canada recommends thirty to sixty minutes of moderate physical activity at least four days a week. So go for a run, a walk, or a bike ride. Any kind of cardio will do, as long as you are consistent with the frequency and duration of your workouts. Eat healthy Evidence shows that eating a balanced, lower-fat diet can reduce the risk of cancer. Choose lower-fat dairy products and leaner meats. Eat more whole grain products (breads and cereals); certain fibres have been shown to block estrogen’s ability to stimulate cell growth. Eat five to ten servings of fruits and vegetables—they are filled with cancer-fighting phytochemicals. Drink green tea Spanish and British scientists have discovered that EGCG, an antioxidant found in green tea, can prevent cancer cells from growing. The exact recommended green tea intake has yet to be determined, but it appears that a cup a day may be sufficiently beneficial. Maintain a healthy weight Extra pounds equal higher levels of estrogen. Combine exercise with a balanced, low-fat diet to maintain a healthy weight for your height. Calculate your body-mass index using divine.ca’s BMI calculator to help determine your ideal weight. Quit smoking Although the effects of cigarette smoking are not fully understood and more research is needed, Health Canada states that there may be an association between breast cancer and tobacco smoking or breathing second-hand smoke.
Breastfeed Breastfeeding appears to offer some women protection against breast cancer, as lactation helps suppress estrogen production. If you are a new mother, consider breastfeeding your baby. For your baby’s health, Health Canada recommends exclusive breastfeeding for at least the first four months of life. For your health, 15 (cumulative) months of breast feeding in your lifetime can offer significant protection against breast cancer. Drink less alcohol Evidence suggests that women who drink alcohol have a higher risk of breast cancer. The more alcohol a woman drinks, the higher her risk. Keep the boozing to a minimum and limit your intake to one alcoholic drink a day. Sleep more Not getting enough sleep can lead to excessive estrogen production, which has been linked to breast cancer. Try getting at least eight hours of sleep a night. Increase your folic acid and vitamin B6 intake Folic acid and vitamin B6 are important parts of our diets: they help make and repair DNA, and damaged DNA has been linked to cancer. A research from the Harvard School of Public Health has also found that a diet high in these nutrients can protect women against the increased risk of breast cancer caused by alcohol. Since alcohol interferes with the body’s ability to use folic acid, the extra folic acid seems to be most protective in women who drink. Eat plenty of dark green leafy vegetables, legumes and citrus fruits for folic acid, and meat, poultry, fish, potatoes, bananas and beans for vitamin B6. Of course, vitamin supplements can also supply these cancer fighting nutrients. _____________________________________________________________ |
Please review the information here also: http://www.wellnessforlifecenter.org/womens_health.shtml
Tuesday, October 24. 2006
Breaking News on Supplements & Nutrition - Europe | |
Low selenium linked to higher risk of osteoarthritis
11/14/2005- Insufficient levels of selenium may raise the risk of knee osteoarthritis, US researchers will report tomorrow. A team from the University of North Carolina at Chapel Hill found that for every additional tenth of a part per million of selenium in volunteers' bodies, there was a 15-20 per cent decrease in their risk of knee osteoarthritis. The work, based on data gathered from 940 participants, is thought to be the first to link the trace mineral to joint health. Arthritis severity was directly related to how low selenium levels were. "Our results suggest that we might be able to prevent or delay osteoarthritis of the knees and possibly other joints in some people if they are not getting enough selenium,” said study leader Dr Joanne Jordan. The findings, to be presented in San Diego tomorrow at the annual meeting of the American College of Rheumatology, could be particularly important for populations in Europe. Research published in 2002 revealed that selenium levels in British bread-making wheats are 10 to 50 times lower than in their American or Canadian counterparts, owing to reduced levels of the mineral in UK soil and lower pollution. Daily intake of the mineral is therefore often lower than the recommended amount in Britain. At the same time, incidence of osteoarthritis is rising in most developed countries in conjunction with an ageing population and obesity, a major risk factor for osteoarthritis of the knee. The UK currently has the eighth highest obesity rate in the world. In the past year, more than 2 million Britons visited their GP because of osteoarthritis. The US team first suspected that selenium might play a role in preventing osteoarthritis after observing that in severely selenium-deficient areas of China, people frequently develop Kashin-Beck disease, which causes joint problems relatively early in life. They selected pariticipants in the major Johnston County Osteoarthritis Project, and divided them into three groups based on the selenium levels measured in toenail clippings. Those with the highest selenium levels faced a 40 per cent lower risk of knee osteoarthritis than those in the lowest-selenium group. "Those in the highest selenium group had only about half the chance of severe osteoarthritis or disease in both knees. Some of the findings were even stronger in African-Americans and women," said Jordan. She added that there appears to be a clear relationship between selenium and osteoarthritis. The mechanism behind this link needs to be further investigated in the laboratory but the researchers believe the mineral might act as a protective antioxidant. "Later, we'll want to expand the study with larger samples and see whether selenium supplementation reduces pain or other symptoms," added Jordan. Copyright - Unless otherwise stated all contents of this web site are © 2000/2005 – Decision News Media SAS – All Rights Reserved. For permission to reproduce any contents of this web site, please email our Syndication department: contact our Syndication department. Full details for the use of materials on this site can be found in the Terms & Conditions.
AmeriSciences Men's and Women's Master Multi contain Selenium. AmeriSciences Joint Ease is an excellent product for Osetoarthritis.
I have been taking EGCG supplement capsules personally over the last few months. I have also been aggressively recommending it to my patients for potentially numerous medical benefits. Over the same period of time many of you have been similarly bombarded with information about epigallocatechin gallate (EGCG) from me. Now read this summary of an article from the Mayo Clinic College of Medicine, Division of Hematology soon to be published in the journal Leukemia Research. This is really exciting stuff. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies.
Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE.
Mayo Clinic College of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Green tea or its constituents have long been touted as a health promoting substance including claims it may have cancer prevention properties. We previously reported the in vitro ability of one tea polyphenol, epigallocatechin gallate (EGCG), to induce apoptotic cell death in the leukemic B-cells from a majority of patients with chronic lymphocytic leukemia (CLL). After the publication of our findings many patients with CLL and other low grade lymphomas began using over-the-counter products containing tea polyphenols despite the absence of evidence to suggest clinical benefit, definition of possible toxicities, or information on optimal dose and schedule. We have become aware of four patients with low grade B-cell malignancies seen in our clinical practice at Mayo Clinic who began, on their own initiative, oral ingestion of EGCG containing products and subsequently appeared to have an objective clinical response. Three of these four patients met criteria for partial response (PR) by standard response criteria. Although spontaneous remission/regression is occasionally observed in individuals with low grade B-cell malignancies, such events are rare. Several patients presented here had documented steady clinical, laboratory, and/or radiographic evidence of progression immediately prior to initiation of over-the-counter green tea products and then developed objective responses shortly after self-initiating this therapy. Such anecdotes highlight the need for clinical trials of tea polyphenols to define the optimal dosing, schedule, toxicities, and clinical efficacy before widespread use can be recommended. An NCI sponsored phase I/II trial of de-caffeinated green tea extracts for patients with asymptomatic, early stage CLL opened at Mayo Clinic in August 2005.
PMID: 16325256 [PubMed - as supplied by publisher]
Sultan H. Rahaman, M.D. President Wellness for Life Center, Inc. info@wellnessforlifecenter.org
Breaking News on Food in Central & Eastern Europe | |
| Green tea extract may slow Huntington’s disease By Stephen Daniells | 09/08/2006- The green tea extract, epigallocatechin gallate (EGCG), may slow the accumulation of proteins that cause Huntington’s disease, German scientists have reported.
The news adds to a growing body of science on the health benefits of green tea, with consumption linked to a lower risk of certain cancers, increased weight loss, and protection against Alzheimer's. Huntington’s disease, along with Alzheimer’s and Parkinson’s, belong to the family of neurodegenerative diseases caused by protein misfolding. The incurable disease is hereditary and has a prevalence of 1 in every 15,000 people. In Germany, about 8,000 cases are currently known, in the UK the figure is reported to be about 5,000, and in the US the figure is about 30,000. The disease is characterize by jerky, uncontrolled movements, an unsteady gait and grimaces leading to its original common name of Huntington’s chorea (from the ancient Greek for “dance”). In 1993, scientists discovered the gene that encodes the mutant protein, the so-called huntingtin protein. A mutation in this protein results in elongation of parts of the protein called polyglutamine chains, which cause the overall huntingtin protein to lose its normal structure. These mutant proteins can not be disposed of by the body and accumulate in the brain of sufferers, eventually being toxic to the nerve cells in the brain. The new research, led by Professor Erich Wanker from the Max Delbrück Center for Molecular Medicine Berlin-Buch (MDC), looked at the effect on EGCG on the aggregation of these mutant proteins in vitro, and found that the green tea extract could interfere with the very early events of this process. The research is published in the September issue journal Human Molecular Genetics (Vol. 15, pp. 2743-2751), and presented by Dagmar Ehrnhoefer this week at the international conference “Neurodegenerative diseases: molecular mechanisms in a functional genomic frameworks” in Berlin. “We demonstrate that the green tea polyphenol epigallocatechin-3-gallate (EGCG) potently inhibits the aggregation of mutant huntingtin protein in a dose-dependent manner,” wrote lead author Dagmar Ehrnhoefer. Professor Wanker’s group used laboratory-based experiments to show that the green tea extract inhibited misfolding of the huntingtin protein in vitro, as well as using fruit flies genetically modified to over-express the mutant protein. The latter experiments showed that the degeneration of the flies’ photoreceptor and motor function improved. “These results indicate that modulators of huntingtin misfolding … like EGCG are likely to reduce polyglutamine -mediated toxicity in vivo,” concluded Ehrnhoefer. Further research is needed, particular to discern if the bioactive doses needed to produce these protective effects could be obtained from drinking green tea, or by taking supplements. The researchers themselves appear to be heading down a pharmaceutical route. Nevertheless, the results are in-line with a growing body of research that reports neuroprotective effects of green tea and its extracts. Green tea is said to contain over four times the concentration of antioxidant catechins than black tea (green tea leaves that have been oxidized by fermentation), about 70 mg catechins per 100 mL compared to 15 mg per 100 mL for black tea. Consumer awareness of the benefits of green tea and green tea extracts continues to rise with growing numbers of studies, from 430 papers in 2000 to almost 1500 in 2003, reporting benefits of the main compounds, catechins. This has seen European demand surge, having reached 500 metric tonnes in 2003. Companies such as DSM, with its Teavigo boasting 95 per cent purity of epigallocatechin gallate (EGCG), and Taiyo International, with its Sunphenon claiming more than 90 per cent purity, position themselves firmly in specific catechin markets. |
I highly recommend a pharmaceutical quality Omega-3 fish oil supplement for cardiac disease risk reduction and risk reduction of many other diseases. Consider AmeriSciences Omega Max at www.amerisciencesproducts.com . The New York Times October 3, 2006 In Europe It’s Fish Oil After Heart Attacks, but Not in U.S. ROME — Every patient in the cardiac care unit at the San Filippo Neri Hospital who survives a heart attack goes home with a prescription for purified fish oil, or omega-3 fatty acids. “It is clearly recommended in international guidelines,” said Dr. Massimo Santini, the hospital’s chief of cardiology, who added that it would be considered tantamount to malpractice in Italy to omit the drug. In a large number of studies, prescription fish oil has been shown to improve survival after heart attacks and to reduce fatal heart rhythms. The American College of Cardiology recently strengthened its position on the medical benefit of fish oil, although some critics say that studies have not defined the magnitude of the effect. But in the United States, heart attack victims are not generally given omega-3 fatty acids, even as they are routinely offered more expensive and invasive treatments, like pills to lower cholesterol or implantable defibrillators. Prescription fish oil, sold under the brand name Omacor, is not even approved by the Food and Drug Administration for use in heart patients. “Most cardiologists here are not giving omega-3’s even though the data supports it — there’s a real disconnect,” said Dr. Terry Jacobson, a preventive cardiologist at Emory University in Atlanta. “They have been very slow to incorporate the therapy.” The fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said. Because prescription fish oil is not licensed to prevent heart disease in the United States, drug companies may not legally promote it for that purpose at conferences, in doctors’ offices, to patients or even on the Internet. “If people paid more attention to guidelines, more people would be on the drug,” Dr. Jacobson said. “But pharmaceutical companies can’t drive this change. The fact that it’s not licensed for this has definitely kept doctors away.” For example, on Solvay Pharmaceutical’s Web site for Omacor, www.solvay-omacor.com, the first question a user sees is, “Are you a U.S. citizen?” If the answer is yes, the user is sent to a page where heart attacks are not mentioned. (In the United States, Omacor is licensed only to treat the small number of people with extremely high blood triglyceride levels.) So community doctors do not learn how to use the drug. Lack of F.D.A. approval also means that insurers will not pay for treatment with Omacor. Approval from the agency for the use of the drug in heart disease is not expected soon. A study published last month in The Journal of the American Board of Family Medicine found that only 17 percent of family doctors were likely to prescribe fish oil to their patients, including patients who had suffered a heart attack. There was a great need, the authors concluded, to “improve awareness of this important advice.” The fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said. “Using this medicine is very popular here in Italy, I think partly because so many cardiologists in this country participated in the studies and were aware of the results,” said Dr. Maria Franzosi, a researcher at the Mario Negri Institute in Milan. “In other countries, uptake may be harder because doctors think of it as just a dietary intervention.” In the largest study of fish oil — conducted more than a decade ago — Italian researchers from the Gissi Group (Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto), gave 11,000 patients one gram of prescription fish oil a day after heart attacks. After three years, the study found that the number of deaths was reduced by 20 percent and that the number of sudden deaths by 40 percent, compared with a control group. Later studies have continued to yield positive results, although some scientists say there are still gaps in knowledge. This summer, a critical review of existing research in BMJ, The British Medical Journal, “cast doubt over the size of the effect of these medications” for the general population, said Dr. Roger Harrison, an author of the paper, “but still suggested that they might benefit some people as a treatment.” Dr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish. Still, he acknowledged that it was difficult to eat foods containing a gram of omega-3 acids each day. “If you ask me do I take omega-3 supplements every day, then, embarrassingly, the answer is yes,” said Dr. Harrison, a professor at Bolton Primary Care Trust of the University of Manchester in England. “I, too, am caught up in this hectic world where I have little time to shop and prepare the healthy foods I know I should be eating,” he said. It seems natural for Italy to be at the forefront of the fish oil trend and home to the largest clinical trials. Scientists have long noted that Mediterranean diets are salubrious for the heart and theorized that the high content of broiled and baked fish might be partly responsible. But the landmark Gissi-Prevenzione trial of fish oil had methodological weaknesses: the patients treated with prescription fish oil pills were compared with untreated patients, rather than with patients given a dummy pill. This meant that, despite impressive results, the trial did not meet the F.D.A.’s standards for approval. Yet by 2004, regulators in almost all European countries, including Spain, France and Britain, had approved Omacor for use in heart attack patients. Marylou Rowe, a spokeswoman for Reliant Pharmaceuticals, which owns the license for the drug in the United States, said that further trials of Omacor would be needed for it to be licensed for heart attack patients in the United States. But she refused to discuss a timetable. The American College of Cardiology now advises patients with coronary artery disease to increase their consumption of omega-3 acids to one gram a day, but it does not specify if this should be achieved by eating fish or by taking capsules. But over-the-counter preparations of fish oil have much less rigorous quality control and are often blends of the two fish oils know to be beneficial in heart disease with other less useful fatty acids. For that reason, Dr. Jacobson of Emory gives the prescription drug, “off label,” to cardiac patients, even though the F.D.A. has not approved it for that use. “Then I know exactly what they’re getting, and there is no mercury,” he said. He said he tells patients who cannot afford the prescription version that they can take the over-the-counter supplements, although there is uncertainty about the dose and they probably need three to four pills a day. In Europe, meanwhile, research on prescription fish oil, which is now thought to act by stabilizing cell membranes, has gained momentum. The Gissi Group is conducting two huge trials using fish oil in patients with abnormal heart rhythms and in patients with heart failure.
Monday, October 23. 2006
I highly recommend a pharmaceutical grade nutritional supplement with Lutein, Astaxanthin, zinc and other antioxidants to help reduce the risk of Macular Degeneration. Here is an interesting article. SCIENCE FILEPlant Pigment May Reverse Vision LossBy Thomas H. Maugh IILos Angeles Times Staff Writer
April 10, 2004
Lutein, a yellow pigment found in dark green leafy vegetables like spinach, kale and collard greens, can reverse some of the symptoms of age-related macular degeneration, the leading cause of visual disability in the United States, according to a new study.
As many as 6 million Americans have at least some vision loss because of the disease, and the number is expected to double by 2025 as the baby boom generation ages.
Lutein has previously been shown in several small studies — as well as one major trial to be announced later this month — to delay the onset of macular degeneration. The new study, published last week in the Journal of the American Optometric Assn., was the first to show that it could actually reverse symptoms. But the study was small, involving only 90 subjects, and needs to be repeated on a much larger number of people.
Macular degeneration, which involves genetic and nutritional components, occurs in the area of the eye that provides the central field of vision, interfering with a person's ability to see details and eventually leading to complete blindness. There is no successful treatment for the disease.
In the study, Dr. Stuart Richer of the North Chicago VA Medical Center and his colleagues gave 10 milligrams of lutein a day to 30 people with the disease, 10 milligrams of lutein and 10 milligrams of an antioxidant to another 30, and a placebo to a third group of 30.
Over the year of the study, those patients getting either formulation of lutein had a modest increase in visual acuity, Richer said, while those receiving a placebo got worse. "This is unprecedented," Richer said. "But the data doesn't support calling it a treatment because the study was so small. I prefer to call it an intervention."
Richer says he tells his elderly patients to eat 3 to 4 ounces of spinach — the equivalent of 10 milligrams of lutein — at least three or four times a week, especially if they are smokers or have blue eyes, both of which are risk factors for the disease. If they can't or won't eat spinach, he recommends supplements. If you want other stories on this topic, search the Archives at latimes.com/archives.
Article licensing and reprint options Copyright 2004 Los Angeles Times Consider "AmeriSciences Antioxidant Plus" at www.amerisciencesproducts.com Look under Products/Preventative Nutrition.
Overweight and ObesityHealth ConsequencesOverweight and obese individuals (BMI of 25 and above) are at increased risk for physical ailments such as (NIH pp.12-20; Stunkard p. 224) - High blood pressure, hypertension
- High blood cholesterol, dyslipidemia
- Type 2 (non-insulin dependent) diabetes
- Insulin resistance, glucose intolerance
- Hyperinsulinemia
- Coronary heart disease
- Angina pectoris
- Congestive heart failure
- Stroke
- Gallstones
- Cholescystitis and cholelithiasis
- Gout
- Osteoarthritis
- Obstructive sleep apnea and respiratory problems
- Some types of cancer (such as endometrial, breast, prostate, and colon)
- Complications of pregnancy
- Poor female reproductive health (such as menstrual irregularities, infertility, irregular ovulation)
- Bladder control problems (such as stress incontinence)
- Uric acid nephrolithiasis
- Psychological disorders (such as depression, eating disorders, distorted body image, and low self esteem).
Reference Stunkard AJ, Wadden TA. (Editors) Obesity: theory and therapy, Second Edition. New York: Raven Press, 1993. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Bethesda, Maryland: Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 1998. Review AmeriSciences Slim Science Program. Visit www.amerisciencesproducts.com. Look under Products/Weight Loss.
January 15 2003 • Volume 33 • Number 2 Nutraceuticals Gain Favor for Treatment of Osteoarthritis Glucosamine, chondroitin Michele G. Sullivan Mid-Atlantic Bureau
ORLANDO, FLA. — Dismissed a decade ago as “snake oil,” glucosamine and chondroitin sulfate have gained respect as treatments for osteoarthritis, Dr. David Hungerford, said at a symposium on hip and knee arthroplasty sponsored by the Current Concepts Institute.
These nutritional supplements are safe and chondroprotective, said Dr. Hungerford, an orthopedic surgeon at Johns Hopkins University, Baltimore.
A 1999 study that followed 199 patients being treated for osteoarthritis of the hand found that, over 3 years, 8% of those who took chondroitin sulfate developed new joint lesions as compared to 29% of the control group.
A 2-year study published in 2001 examined the radiographic outcomes of 210 patients with knee osteoarthritis.
Patients taking chondroitin sulfate showed no joint changes, while those on placebo showed significant joint space narrowing.
Another 2-year, placebo-controlled study published in 2001 found that patients who had knee osteoarthritis and took glucosamine experienced increased function, less pain, and less joint-space narrowing than patients who did not take the supplement.
Dr. Hungerford offered one caveat to these findings: The chondroitin and glucosamine products used in clinical studies contain optimum amounts of the active ingredients. Among nutritional supplements available to consumers, it can be difficult to find a brand that contains the optimum amount of active ingredients.
A recent study of 32 brands of glucosamine showed that 17 had less than 50% of the level of active ingredients claimed on the label and that some of those brands had no active ingredient at all.
“It's important to guide patients to products whose ingredients have been thoroughly tested,” he said.
Copyright © 2004 by International Medical News Group, an Elsevier company. Click for restrictions. I recommend AmeriSciences Joint Ease. Visit www.amerisciencesproducts.com . Look under Products/Preventative Nutrition.
FAMILY PRACTICE NEWS March 15 2004 • Volume 34 • Number 6 Antioxidant Therapy Quickly Improves Endometriosis Pain Kate Johnson Contributing Writer SAN ANTONIO — Two months of high-dose vitamin E and C therapy was associated with significant improvement in endometriosis pain and a reduction in inflammatory markers in a study of 59 women.
“We didn't really expect that patients would actually report anything clinically after only 2 months, but it's really impressive. They are doing much better,” said Dr. Nino Kavtaradze, an ob.gyn. resident at Emory University in Atlanta.
The study, presented at the annual meeting of the American Society for Reproductive Medicine, included 59 women, aged 19-41, with pelvic pain and a history of endometriosis and/or infertility.
Inflammatory markers were measured in blood, which was drawn from all women at the beginning and end of the study, and in peritoneal fluid, which was collected by laparoscopy at the end of the study.
Pain levels were evaluated at baseline and then monthly during the study.
A total of 46 patients were given vitamin E (1,200 IU daily) and vitamin C (1,000 mg daily) for 2 months before undergoing laparoscopy; the remaining 13 patients received placebo.
“We have shown previously that endometriosis is characterized by signs of increased oxidative stress,” said Dr. Nalini Santanam, Ph.D., who led the investigation into inflammatory markers. “Inflammation can be induced by oxidative stress, so our theory was that antioxidants might reduce the inflammatory markers.
Indeed, at the end of the study, the levels of inflammatory markers in peritoneal fluid of women who received the vitamins were significantly lower than the levels in the placebo group.
Levels of inflammatory markers in plasma were the same in both groups, “suggesting that these markers are locally generated in the peritoneal cavity,” commented Dr. Santanam of the department of obstetrics and gynecology at Emory.
In the vitamin group, 43% of the women reported an improvement in everyday pain, compared with none of the women in the placebo group. Thirty-seven percent of the vitamin group had decreased dysmenorrhea, compared with 36% of the placebo group, and 24% of the vitamin group had decreased dyspareunia compared with none of the placebo group.
“This is an exciting finding that such a simple and safe therapy might have such dramatic effects on endometriosis,” Dr. Santanam said.
I recommend AmeriSciences Women's Master Multi and AmeriSciences Antioxidant Plus. |
Visit www.amerisciencesproducts.com Look under Products/Women's Health and Preventative Nutrition.
Green Tea Component Kills Leukemia Cells | |
THURSDAY, April 8 (HealthDayNews) -- A component of green tea helps kill cells of B-cell chronic lymphocytic leukemia (CLL), the second most common leukemia in American adults, according to new research. Mayo Clinic researchers found that the component, called epigallocatechin-3-gallate (EGCG), destroys leukemia cells by interrupting the communication signals they need to survive. The research appears online in the journal Blood. CLL is most often diagnosed in people in their mid-to-late 60s. Chemotherapy is used to treat the most severe cases, but there is no cure for CLL. In this study, the Mayo scientists found that EGCG prompted leukemia cells to die in eight of 10 patient samples tested in a laboratory. "We're continuing to look for therapeutic agents that are nontoxic to the patient but kill cancer cells, and this finding with EGCG is an excellent start," study leader Dr. Neil E. Kay said in a prepared statement. "Understanding this mechanism and getting these positive early results gives us a lot to work with in terms of offering patients with this disease more effective, easily tolerated therapies earlier." More information The U.S. National Cancer Institute (news - web sites) has more about CLL. Review AmeriSciences Slim with Green Tea. Check under Products/Weight Loss at www.amerisciencesproducts.com
|